RAYNE ROUCE to T-Lymphocytes
This is a "connection" page, showing publications RAYNE ROUCE has written about T-Lymphocytes.
Connection Strength
2.353
-
Reverse translational studies inform dual-targeted CAR T-cell design. Blood. 2022 08 04; 140(5):409-410.
Score: 0.405
-
The earlier the better: timely mitigation of CRS. Blood. 2019 12 12; 134(24):2119-2120.
Score: 0.337
-
Equal opportunity CAR T cells. Blood. 2017 06 22; 129(25):3275-3277.
Score: 0.284
-
Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental Group. Transplant Cell Ther. 2026 Mar; 32(3):261-276.
Score: 0.127
-
Mediport use as an acceptable standard for CAR T cell infusion. Front Immunol. 2023; 14:1239132.
Score: 0.110
-
Access offsets poverty in quest for CAR T cells. Blood. 2023 02 09; 141(6):558-560.
Score: 0.105
-
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
Score: 0.091
-
Replacing CAR-T cell resistance with persistence by changing a single residue. J Clin Invest. 2020 06 01; 130(6):2806-2808.
Score: 0.087
-
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
Score: 0.083
-
A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells. J Transl Med. 2019 07 24; 17(1):240.
Score: 0.082
-
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
Score: 0.077
-
In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
Score: 0.077
-
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
Score: 0.071
-
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296.
Score: 0.071
-
Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol. 2017 03; 176(5):688-704.
Score: 0.068
-
Forecasting Cytokine Storms with New Predictive Biomarkers. Cancer Discov. 2016 06; 6(6):579-80.
Score: 0.066
-
Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas. Blood Adv. 2025 Apr 08; 9(7):1658-1669.
Score: 0.030
-
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults. Blood Adv. 2024 07 09; 8(13):3544-3548.
Score: 0.029
-
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Rep Med. 2024 Jul 16; 5(7):101628.
Score: 0.029
-
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
Score: 0.029
-
INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults. Transplant Cell Ther. 2024 06; 30(6):565-579.
Score: 0.028
-
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 03 28; 143(13):1231-1241.
Score: 0.028
-
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280.
Score: 0.019
-
Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther. 2017 08 02; 25(8):1769-1781.
Score: 0.018